紫杉烷类药物在晚期胃癌治疗中的应用
Taxanes in the Treatment of Advanced Gastric Cancer.
作者信息
Kang Byung Woog, Kwon Oh-Kyoung, Chung Ho Young, Yu Wansik, Kim Jong Gwang
机构信息
Department of Oncology/Hematology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Kyungpook National University Cancer Research Institute, 807 Hogukno, buk-gu, Daegu 41404, Korea.
Department of Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu 41494, Korea.
出版信息
Molecules. 2016 May 17;21(5):651. doi: 10.3390/molecules21050651.
Abstract
Although rapid advances in treatment options have improved the prognosis of advanced gastric cancer (AGC), it remains a major public health problem and the second leading cause of cancer-related deaths in the world. Taxanes (paclitaxel and docetaxel) are microtubule stabilizing agents that inhibit the process of cell division, and have shown antitumor activity in the treatment of AGC as a single or combination chemotherapy. Accordingly, this review focuses on the efficacy and tolerability of taxanes in the first- or second-line chemotherapy setting for AGC.
摘要
尽管治疗方案的迅速进展改善了晚期胃癌（AGC）的预后，但它仍然是一个主要的公共卫生问题，并且是全球癌症相关死亡的第二大主要原因。紫杉烷类（紫杉醇和多西他赛）是抑制细胞分裂过程的微管稳定剂，并且已显示出作为单一疗法或联合化疗在AGC治疗中的抗肿瘤活性。因此，本综述着重于紫杉烷类在AGC一线或二线化疗中的疗效和耐受性。
相似文献
1
Taxanes in the Treatment of Advanced Gastric Cancer.紫杉烷类药物在晚期胃癌治疗中的应用
Molecules. 2016 May 17;21(5):651. doi: 10.3390/molecules21050651.
2
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.用于治疗晚期胃癌的非铂类化疗：5-氟尿嘧啶、紫杉烷类和伊立替康。
World J Gastroenterol. 2014 May 14;20(18):5396-402. doi: 10.3748/wjg.v20.i18.5396.
3
Paclitaxel-resistant recurrent gastric cancer responsive to docetaxel: a case report.对多西他赛敏感的耐紫杉醇复发性胃癌：一例报告
Gan To Kagaku Ryoho. 2011 Apr;38(4):643-5.
4
[Two cases of advanced gastric cancer in which paclitaxel proved effective after resistance to docetaxel].
Gan To Kagaku Ryoho. 2007 Oct;34(10):1647-50.
5
Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer.
Gan To Kagaku Ryoho. 2012 Oct;39(10):1511-5.
6
Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.多西他赛、顺铂和S-1三联化疗难治的晚期胃癌中紫杉烷单药治疗的疗效和安全性：一项多中心回顾性研究
Cancer Chemother Pharmacol. 2017 Sep;80(3):575-582. doi: 10.1007/s00280-017-3397-3. Epub 2017 Jul 20.
7
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.紫杉烷类药物在乳腺癌辅助治疗和新辅助治疗中的新作用：潜力与问题
Surg Clin North Am. 2003 Aug;83(4):943-71. doi: 10.1016/S0039-6109(03)00071-9.
8
Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer.含紫杉类药物的联合化疗方案作为晚期胃癌一线治疗的疗效和安全性。
Clin Exp Med. 2023 Jun;23(2):381-396. doi: 10.1007/s10238-022-00824-1. Epub 2022 Apr 16.
9
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.紫杉烷类用于乳腺癌治疗：基于证据的随机II期和III期试验综述
Clin Breast Cancer. 2000 Apr;1(1):32-40; discussion 41-2. doi: 10.3816/CBC.2000.n.002.
10
Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer.在人胃癌异种移植模型中提高热靶向紫杉烷递送效率。
J Pharm Sci. 2008 Aug;97(8):3170-81. doi: 10.1002/jps.21194.
引用本文的文献
1
Enhancing the Chemosensitivity of MKN-45 Gastric Cancer Cells to Docetaxel via Suppression: A Novel Therapeutic Strategy.通过抑制增强MKN-45胃癌细胞对多西他赛的化疗敏感性：一种新的治疗策略。
Life (Basel). 2024 Nov 26;14(12):1546. doi: 10.3390/life14121546.
2
Paeoniflorin Induces ER Stress-Mediated Apoptotic Cell Death by Generating Nox4-Derived ROS under Radiation in Gastric Cancer.芍药苷通过在胃癌中产生 Nox4 衍生的 ROS 诱导内质网应激介导的细胞凋亡死亡。
Nutrients. 2023 Dec 13;15(24):5092. doi: 10.3390/nu15245092.
3
Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery.基于计算机的策略在蛋白质-蛋白质相互作用药物研发中的发展。
Molecules. 2018 Aug 6;23(8):1963. doi: 10.3390/molecules23081963.
4
Dental pulp stem cells used to deliver the anticancer drug paclitaxel.用于递送抗癌药物紫杉醇的牙髓干细胞。
Stem Cell Res Ther. 2018 Apr 12;9(1):103. doi: 10.1186/s13287-018-0831-3.
5
Morusin inhibits cell proliferation and tumor growth by down-regulating c-Myc in human gastric cancer.桑色素通过下调人胃癌中的c-Myc抑制细胞增殖和肿瘤生长。
Oncotarget. 2017 Jul 14;8(34):57187-57200. doi: 10.18632/oncotarget.19231. eCollection 2017 Aug 22.
6
High BIM mRNA levels are associated with longer survival in advanced gastric cancer.高BIM信使核糖核酸水平与晚期胃癌患者更长的生存期相关。
Oncol Lett. 2017 Mar;13(3):1826-1834. doi: 10.3892/ol.2017.5660. Epub 2017 Feb 1.
7
Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.晚期胃癌伴腹膜播散患者每三周单次给予纳米白蛋白结合型紫杉醇的长期成功管理。
Intern Med. 2017;56(8):921-923. doi: 10.2169/internalmedicine.56.7783. Epub 2017 Apr 15.
8
Silencing of ATP4B of ATPase H/K Transporting Beta Subunit by Intragenic Epigenetic Alteration in Human Gastric Cancer Cells.人胃癌细胞中基因内表观遗传改变导致ATP酶H/K转运β亚基ATP4B沉默
Oncol Res. 2017 Mar 13;25(3):317-329. doi: 10.3727/096504016X14734735156265.
本文引用的文献
1
A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA).卡巴他赛用于既往化疗失败的晚期胃癌患者的I期研究（GASTANA）。
Cancer Chemother Pharmacol. 2015 Feb;75(2):309-18. doi: 10.1007/s00280-014-2638-y. Epub 2014 Dec 9.
2
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.多西他赛联合奥沙利铂加或不加氟尿嘧啶或卡培他滨治疗转移性或局部复发性胃癌的随机 II 期研究。
Ann Oncol. 2015 Jan;26(1):149-156. doi: 10.1093/annonc/mdu496.
3
Preclinical profile of cabazitaxel.卡巴他赛的临床前概况。
Drug Des Devel Ther. 2014 Oct 13;8:1851-67. doi: 10.2147/DDDT.S64940. eCollection 2014.
4
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.雷莫芦单抗联合紫杉醇对比安慰剂联合紫杉醇治疗既往治疗的晚期胃或胃食管结合部腺癌患者（RAINBOW）：一项双盲、随机、III 期临床试验。
Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.
5
Paclitaxel formulations: challenges and novel delivery options.紫杉醇制剂：挑战与新型给药途径。
Curr Drug Deliv. 2014;11(6):666-86. doi: 10.2174/1567201811666140609154949.
6
Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer.白蛋白结合型紫杉醇纳米粒二线治疗不可切除或复发性胃癌的 II 期临床试验。
Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7.
7
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.多西他赛对比积极症状控制治疗难治性胃食管腺癌（COUGAR-02）：一项开放标签、3 期随机对照试验。
Lancet Oncol. 2014 Jan;15(1):78-86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10.
8
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer.一项比较每周多西他赛/顺铂与每周多西他赛/奥沙利铂作为晚期胃癌一线治疗的随机 II 期研究。
Cancer Chemother Pharmacol. 2014 Jan;73(1):163-9. doi: 10.1007/s00280-013-2334-3. Epub 2013 Nov 8.
9
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.随机、开放标签、III 期研究比较了伊立替康与紫杉醇在氟嘧啶加铂类化疗失败后无严重腹膜转移的晚期胃癌患者中的疗效：WJOG4007 试验。
J Clin Oncol. 2013 Dec 10;31(35):4438-44. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4.
10
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.雷莫芦单抗单药治疗既往治疗的晚期胃或胃食管结合部腺癌（REGARD）：一项国际、随机、多中心、安慰剂对照、3 期临床试验。
Lancet. 2014 Jan 4;383(9911):31-39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3.
Zotero 插件